MedTrace Logo

Opioid Antagonism in Hypogonadotropic Hypogonadism

NCT04975334 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2026-05-01

Study results available
· View outcomes & findings →

Summary

The goal of this study is to evaluate the effects of opioid antagonists on the hypothalamic-pituitary-gonadal axis in subjects with hypogonadotropic hypogonadism (HH).

Conditions

  • Hypogonadotropic Hypogonadism
  • Low Testosterone

Interventions

DRUG

Naloxone

One bolus of naloxone

Sponsors & Collaborators

  • Stephanie B. Seminara, MD

    lead OTHER

Principal Investigators

  • Stephanie Seminara, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-18
Primary Completion
2025-09-26
Completion
2025-09-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04975334 on ClinicalTrials.gov